181 related articles for article (PubMed ID: 11590513)
1. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.
Duran S; Spire B; Raffi F; Walter V; Bouhour D; Journot V; Cailleton V; Leport C; Moatti JP;
HIV Clin Trials; 2001; 2(1):38-45. PubMed ID: 11590513
[TBL] [Abstract][Full Text] [Related]
2. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens.
Duong M; Piroth L; Grappin M; Forte F; Peytavin G; Buisson M; Chavanet P; Portier H
HIV Clin Trials; 2001; 2(2):128-35. PubMed ID: 11590521
[TBL] [Abstract][Full Text] [Related]
4. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
6. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
Chou R; Fu R; Huffman LH; Korthuis PT
Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
[TBL] [Abstract][Full Text] [Related]
7. [Problems in the management of HIV infection in clinical practice. Patients still on dual therapy 8 years after the introduction of HAART].
Manfredi R
Recenti Prog Med; 2003 Nov; 94(11):506-7. PubMed ID: 14679919
[TBL] [Abstract][Full Text] [Related]
8. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
9. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.
Spire B; Duran S; Souville M; Leport C; Raffi F; Moatti JP;
Soc Sci Med; 2002 May; 54(10):1481-96. PubMed ID: 12061483
[TBL] [Abstract][Full Text] [Related]
10. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
12. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.
Røge BT; Barfod TS; Kirk O; Katzenstein TL; Obel N; Nielsen H; Pedersen C; Mathiesen LR; Lundgren JD; Gerstoft J
HIV Med; 2004 Sep; 5(5):344-51. PubMed ID: 15369509
[TBL] [Abstract][Full Text] [Related]
13. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
14. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART.
Guaraldi G; Murri R; Orlando G; Orlandi E; Sterrantino G; Borderi M; Grosso C; Cattelan AM; Nardini G; Beghetto B; Antinori A; Esposito R; Wu AW
HIV Clin Trials; 2003; 4(2):99-106. PubMed ID: 12671777
[TBL] [Abstract][Full Text] [Related]
15. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
16. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
17. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors.
Maggiolo F; Ravasio L; Ripamonti D; Gregis G; Quinzan G; Arici C; Airoldi M; Suter F
Clin Infect Dis; 2005 Jan; 40(1):158-63. PubMed ID: 15614706
[TBL] [Abstract][Full Text] [Related]
18. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
19. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
[TBL] [Abstract][Full Text] [Related]
20. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).
Savès M; Vandentorren S; Daucourt V; Marimoutou C; Dupon M; Couzigou P; Bernard N; Mercié P; Dabis F
AIDS; 1999 Dec; 13(17):F115-21. PubMed ID: 10597772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]